Your browser doesn't support javascript.
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose (preprint)
researchsquare; 2022.
ما قبل الطباعة ي الانجليزية | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2176472.v1
ABSTRACT
The prime-boost COVID-19 mRNA vaccination strategy has proven to be effective against severe COVID-19 disease and death. However, concerns have been raised due to decreasing neutralizing antibody levels after COVID-19 vaccination and due to the emergence of new immuno-evasive SARS-CoV-2 variants that may require additional booster vaccinations. Here we show that within the vaccinated health care workers (HCWs) the third mRNA vaccine dose recalls both humoral and T cell-mediated immune responses and induces high levels of neutralizing antibodies against Omicron BA.1 and BA.2 variants. Three weeks after the third vaccine dose, SARS-CoV-2 wild type spike protein-specific CD4+ and CD8+ T cells are observed in 82% and 71% of HCWs, respectively, and the T cells cross-recognize both Omicron BA.1 and BA.2 spike peptides. Although the levels of neutralizing antibodies against Omicron BA.1 and BA.2 decline 2.5 to 3.8-fold three months after the third dose, Th1-type memory CD4+ T cell responses are maintained for at least 7 months post the second dose and 3 months post the third vaccine dose suggesting durable immune protection.
الموضوعات

النص الكامل: متاح مجموعة: المطبوعات المسبقة قاعدة البيانات: PREPRINT-RESEARCHSQUARE الموضوع الرئيسي: Death / COVID-19 اللغة: الانجليزية السنة: 2022 نوع: ما قبل الطباعة

المراجع ذات الصلة

MEDLINE

...
LILACS

LIS


النص الكامل: متاح مجموعة: المطبوعات المسبقة قاعدة البيانات: PREPRINT-RESEARCHSQUARE الموضوع الرئيسي: Death / COVID-19 اللغة: الانجليزية السنة: 2022 نوع: ما قبل الطباعة